Multicomponent chemical enhancer formulations for transdermal drug delivery: More is not always better

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 175-180

  Arora, Anubhav ^a,b   Kisak, Edward ^c   Karande, Pankaj ^d   Newsam, John ^c   Mitragotri, Samir ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fqubed Inc   (United States)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

High throughput screening; Irritation; Optimization; Personal care

Indexed keywords

CHEMICAL ENHANCERS; HEURISTIC RULES; HIGH POTENCY; HIGH THROUGHPUT SCREENING; HIGHER ORDER; HUMAN SKIN; MULTICOMPONENTS; PERMEATION ENHANCEMENT; PERMEATION ENHANCERS; PERSONAL CARE; SKIN IRRITATION; SKIN PERMEATION; SYNERGISTIC INTERACTION; TRANSDERMAL DELIVERY; TRANSDERMAL DRUG DELIVERY;

CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; OPTIMIZATION; THROUGHPUT;

LIBRARIES;

1 METHYL 2 PYRROLIDINONE; CETRIMIDE; CINEOLE; DODECYLAMINE; EXCIPIENT; HEXADECYLDIMETHYL AMMONIO PROPANE SULFONATE; NICOTINE SULFATE; OCTYL SULFATE SODIUM; OLEATE SODIUM; POLYETHYLENE GLYCOL DODECYL ETHER; TETRACAINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG FORMULATION; DRUG POTENCY; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; SWINE; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; SKIN; SWINE;

EID: 77952672953     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.015     Document Type: Article

References (20)

1. Reichert J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 2002, 4(2):110-118.
2. Reichert J.M. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. Trends Biotechnol. 2000, 18(9):364-369.
3. Reichert J.M. Trends in the development and approval of monoclonal antibodies for viral infections. Biodrugs 2007, 21(1):1-7.
4. Kettwich S.C., Sibbitt W.L., Kettwich L.G., Palmer C.J., Draeger H.T., Bankhurst A.D. Patients with needle phobia? Try stress-reducing medical devices. J. Fam. Practice 2006, 55(8):697-700.
5. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Organ 1999, 77(10):789-800.
6. Nelson R. High rate of needle-stick injuries among surgeons. Lancet. Infect. Dis. 2007, 7(8):509-509.
7. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 2004, 19(1):95-103.
8. Prausnitz M.R., Mitragotri S., Langer R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug. Discov. 2004, 3(2):115-124.
9. Elias P.M. Epidermal lipids, barrier function, and desquamation. J. Invest. Dermatol. 1983, 80:S44-S49.
10. Kalia Y.N., Merino V., Guy R.H. Transdermal drug delivery - clinical aspects. Dermatol. Clin. 1998, 16(2):289.
11. Williams A.C., Barry B.W. Penetration enhancers. Adv. Drug Deliver Rev. 2004, 56(5):603-618.
12. Finnin B.C., Morgan T.M. Transdermal penetration enhancers: applications, limitations, and potential. J. Pharm. Sci. 1999, 88(10):955-958.
13. Fang J.Y., Hwang T.L., Fang C.L., Chiu H.C. In vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug. Int. J. Pharm. 2003, 255(1-2):153-166.
14. Asbill C.S., El-Kattan A.F., Michniak B. Enhancement of transdermal drug delivery: chemical and physical approaches. Crit. Rev. Ther. Drug 2000, 17(6):621-658.
15. Karande P., Jain A., Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat. Biotechnol. 2004, 22(2):192-197.
16. Karande P., Mitragotri S. High throughput screening of transdermal formulations. Pharm. Res. 2002, 19(5):655-660.
17. Karande P., Jain A., Ergun K., Kispersky V., Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. P. Natl. Acad. Sci. USA 2005, 102(13):4688-4693.
18. Karande P., Jain A., Arora A., Ho M.J., Mitragotri S. Synergistic effects of chemical enhancers on skin permeability: a case study of sodium lauroylsarcosinate and sorbitan monolaurate. Eur. J. Pharm. Sci. 2007, 31(1):1-7.
19. Karande P., Jain A., Mitragotri S. Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J. Control Release 2006, 110(2):307-313.
20. Karande P., Jain A., Mitragotri S. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Control Release 2006, 115(1):85-93.